As of March 23, 2026, Prelude Therapeutics's top three insider holders are David P Bonita (Director, 10.12Mn shares), Krishna Vaddi (Ceo, 2.00Mn shares), Andrew Combs (Chief Chemistry Officer, 480.12K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David P Bonita | 0 | 10,119,756 | 24 May, 2023 | |
| Krishna Vaddi | Ceo | 1,999,296 | 0 | 27 Mar, 2025 |
| Andrew Combs | Chief Chemistry Officer | 480,123 | 0 | 27 Mar, 2025 |
| Peggy Scherle | Chief Scientific Officer | 172,920 | 0 | 30 Aug, 2021 |
| Krishna Vaddi | Ceo | 0 | 142,553 | 03 Jan, 2025 |
| Jane Huang | President, Cmo | 86,917 | 0 | 07 Oct, 2025 |
| Bryant David Lim | Clo, Interim Cfo, Corp Sec. | 27,400 | 0 | 20 Dec, 2024 |
| Christopher Pierce | Evp And Chief Of Business Oper | 3,750 | 0 | 07 Sep, 2021 |
| Deborah Morosini | Evp, Chief Of Clinical Affairs | 444 | 0 | 17 Dec, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 04 Feb, 2026 | Krishna Vaddi | Employee Stock Option (right to buy) | A | 837,000 | $0.00 | 837,000 | D | A |
| 04 Feb, 2026 | Bryant David Lim | Employee Stock Option (right to buy) | A | 275,000 | $0.00 | 275,000 | D | A |
| 04 Feb, 2026 | Andrew Combs | Employee Stock Option (right to buy) | A | 230,000 | $0.00 | 230,000 | D | A |
| 04 Feb, 2026 | Peggy Scherle | Employee Stock Option (right to buy) | A | 230,000 | $0.00 | 230,000 | D | A |
| 05 Nov, 2025 | Victor Sandor | Director Stock Option (Right to Buy) | A | 121,285 | $0.00 | 121,285 | D | A |
| 17 Oct, 2025 | Katina Dorton | Director Stock Option (Right to Buy) | A | 76,000 | $0.00 | 76,000 | D | A |
| 04 Oct, 2025 | Jane Huang | Common Stock | A | 9,375 | - | 90,272 | D | M |
| 04 Oct, 2025 | Jane Huang | Common Stock | D | 3,355 | $1.47 | 86,917 | D | F |
| 04 Oct, 2025 | Jane Huang | Restricted Stock Unit | D | 9,375 | $0.00 | 18,750 | D | M |
| 04 Jul, 2025 | Jane Huang | Common Stock | A | 9,375 | - | 84,252 | D | M |
| 04 Jul, 2025 | Jane Huang | Common Stock | D | 3,355 | $0.79 | 80,897 | D | F |
| 04 Jul, 2025 | Jane Huang | Restricted Stock Unit | D | 9,375 | $0.00 | 28,125 | D | M |
| 12 Jun, 2025 | Victor Sandor | Director Stock Option (Right to Buy) | A | 38,000 | $0.00 | 38,000 | D | A |
| 12 Jun, 2025 | Bros. Advisors Lp Baker | Non- Qualified Stock Option (right to buy) | A | 76,000 | $0.00 | 76,000 | I | A |
| 12 Jun, 2025 | Mardi Dier | Director Stock Option (Right to Buy) | A | 38,000 | $0.00 | 38,000 | D | A |
| 12 Jun, 2025 | David P Bonita | Director Stock Option (Right to Buy) | A | 38,000 | $0.00 | 38,000 | D | A |
| 12 Jun, 2025 | Bros. Advisors Lp Baker | Non- Qualified Stock Option (right to buy) | A | 76,000 | $0.00 | 76,000 | I | A |
| 04 Apr, 2025 | Jane Huang | Common Stock | A | 9,375 | - | 78,232 | D | M |
| 04 Apr, 2025 | Jane Huang | Common Stock | D | 3,355 | $0.68 | 74,877 | D | F |
| 04 Apr, 2025 | Jane Huang | Restricted Stock Unit | D | 9,375 | $0.00 | 37,500 | D | M |